Company Overview - Ruizhi Pharmaceutical (SZ 300149) announced that on November 13, 2025, it will accept investor research led by Guoxin Securities, with CFO Cha Yinqun addressing investor questions [1] - As of the report, Ruizhi Pharmaceutical has a market capitalization of 5.8 billion yuan [1] Revenue Composition - For the first half of 2025, the revenue composition of Ruizhi Pharmaceutical is as follows: - Pharmaceutical research and development services and production outsourcing accounted for 99.06% - Prebiotic series accounted for 0.52% - Rental income accounted for 0.35% - Other industries accounted for 0.07% [1]

Group 1: Equity Incentive Plan - The company announced a restricted stock incentive plan on April 2025, with the first grant date set for July 11, 2025, at a price of 3.05 yuan per share, granting 44.56 million shares to 123 recipients including management and key personnel [2][3] - The equity incentive expenses for the first three quarters of 2025 amounted to 3,563.69 million yuan; excluding these expenses, the net profit attributable to shareholders was 42.72 million yuan, a year-on-year increase of 169.29% [3] Group 2: Employee Retention and Stability - The company's recent employee turnover rate is at a healthy level, indicating good team stability [3] Group 3: Collaboration with Investment Funds - The company has established investment funds in collaboration with professional investment institutions to enhance the innovative drug industry, leveraging their investment capabilities and risk control [3] Group 4: Performance Outlook - The company aims for a revenue growth rate of no less than 15% in 2025, with net profit (excluding equity incentive payment expenses) expected to be positive [3]

Market Overview - The medical services sector declined by 0.47% on November 14, with the digital human sector leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Notable declines in individual stocks include: - Digital Human: closed at 17.28, down 4.85% with a trading volume of 80,400 shares and a turnover of 1.411 million [1] - Haoyuan Pharmaceutical: closed at 77.20, down 3.54% with a trading volume of 30,800 shares and a turnover of 2.4212 million [1] - Yinos: closed at 48.69, down 2.62% with a trading volume of 14,300 shares and a turnover of 7132.217 [1] - Other notable declines include Taige Pharmaceutical, MediX, and WuXi AppTec, all showing declines between 1.28% and 2.08% [1] Capital Flow - The medical services sector experienced a net outflow of 238 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [3] - Notable capital flows for specific stocks include: - Ruizhi Pharmaceutical: net inflow of 38.93 million yuan from institutional investors, but net outflows from retail and speculative investors [3] - Chengda Pharmaceutical: net inflow of 37.96 million yuan from institutional investors, with significant outflows from speculative investors [3] - Other stocks like Sanbo Brain Science and Jinyu Medical also showed varying net inflows and outflows among different investor types [3]

睿智医药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：创新药、抗癌治 癌、AI医药、CRO概念、阿尔茨海默等。 11月14日，睿智医药盘中上涨2.40%，截至10:48，报11.52元/股，成交1.04亿元，换手率1.94%，总市值 57.37亿元。 资金流向方面，主力资金净流入182.84万元，特大单买入378.07万元，占比3.62%，卖出343.06万元，占 比3.29%；大单买入2199.10万元，占比21.06%，卖出2051.27万元，占比19.65%。 睿智医药今年以来股价涨79.44%，近5个交易日涨6.47%，近20日涨2.58%，近60日跌10.70%。 今年以来睿智医药已经2次登上龙虎榜，最近一次登上龙虎榜为7月29日，当日龙虎榜净买入1.65亿元； 买入总计2.56亿元 ，占总成交额比16.71%；卖出总计9095.17万元 ，占总成交额比5.93%。 资料显示，睿智医药科技股份有限公司位于广东省广州市越秀区东风中路268号交易广场28楼，成立日 期2000年1月26日，上市日期2010年12月22日，公司主营业务涉及医药研发与生产外包服务、微生态营 养、微生态医 ...

Core Insights - The Xinjiang Listed Companies Association organized a learning exchange activity in Shanghai for 27 listed companies and related institutions, focusing on "benchmarking advanced practices and empowering enhancement" [1][2] - The event included training on regulatory policies from the Shanghai Stock Exchange, emphasizing compliance in daily operations, information disclosure, and capital operations [1] - Participants visited four benchmark companies in Shanghai to learn about their advanced experiences in technology innovation, industry operations, corporate governance, and ESG practices [2] Group 1 - The activity aimed to build an efficient learning and cooperation bridge for Xinjiang listed companies [1] - The training provided insights into compliance management and risk prevention, highlighting common issues in information disclosure and regulatory processes [1] - The event facilitated a platform for collaboration between Xinjiang enterprises and Shanghai resources, enhancing awareness of collaborative benchmarking [2] Group 2 - The association plans to continue organizing various learning exchange activities to meet enterprise development needs and promote healthy development in the Xinjiang capital market [2] - The initiative aims to deepen understanding of industrial upgrades, technological innovation, and capital operations [2] - The event strengthened the foundation for high-quality development of Xinjiang listed companies through enhanced capabilities and resource integration [2]

Group 1 - Xinpeng Co., Ltd. provided a guarantee of 50 million yuan for its wholly-owned subsidiary, increasing the total guarantee amount to 1.258 billion yuan, which is 115.47% of the latest audited net assets [1] - Yonggui Electric's subsidiary signed a contract worth 15.8652 million yuan with CRRC Zhuzhou for supplying components for the Wuhan rail transit project [1] - Huada Technology secured project designations from multiple domestic automakers and battery companies, with a total expected sales amount of 2.9 billion yuan, over 80% of which is related to new energy projects [2] Group 2 - China National Machinery International signed a contract for a 5.71 billion yuan hospital construction project in Iraq, which represents 4.68% of the company's expected revenue for 2024 [3] - Fangzhi Technology plans to acquire 100% of Zhixiang Technology for 116 million yuan, focusing on AI-driven smart learning and sports solutions [4] - Demingli is in the early stages of planning a refinancing initiative, with no specific details on the amount or method yet [5] Group 3 - Hesheng Silicon Industry announced a shareholder's plan to reduce holdings by up to 2.29%, equating to 27.0706 million shares [7] - ST Lanhua's subsidiary plans to invest up to 65 million yuan in a juice beverage project in Chongqing [8] - Ruizhi Pharmaceutical developed an automated synthesis system for antibody-drug conjugates and nucleoside monomers in collaboration with East China Normal University [9] Group 4 - Lianying Laser's controlling shareholder intends to reduce holdings by up to 3 million shares, representing 0.88% of the total share capital [10] - Songyuan Safety's controlling shareholder plans to reduce holdings by up to 1% of the total share capital [12] - ST Kaixin's actual controller and major shareholders plan to transfer 5% of the company's shares at a price of 27.85 yuan per share [13] Group 5 - Bojun Technology plans to invest approximately 1 billion yuan in a new automotive parts production base, aiming for an annual capacity of 24 million sets [13] - Litong Electronics' controlling shareholder committed to not reducing holdings for 24 months, while other shareholders plan to reduce a total of 3.03% of shares [14] - Yaoyigou's actual controller intends to transfer 5.23% of shares to a company director at a price of 24 yuan per share [15] Group 6 - Baiwei Storage submitted H-share listing application materials to the China Securities Regulatory Commission [18] - Jinshi Yaya obtained a drug registration certificate for glucosamine sulfate capsules, which are suitable for osteoarthritis treatment [19] - Shangtai Technology plans to invest approximately 4.07 billion yuan in a lithium-ion battery anode material project [19] Group 7 - Xinlitai's shareholder plans to reduce holdings by up to 800,000 shares, representing 0.07% of the total share capital [20] - Yunnan Baiyao elected Zhang Wenxue as the chairman of the board for a three-year term [21] - Huading Co., Ltd. announced that two shareholders plan to reduce their holdings by up to 3% of the total share capital [23] Group 8 - Jiahua Technology's shareholder plans to reduce holdings by up to 0.65% of the total share capital [25]

Core Viewpoint - The company has successfully developed an automated, intelligent, and integrated desktop synthesis system for antibody-drug conjugates (ADC) and nucleotide monomers in collaboration with East China Normal University, which enhances R&D efficiency and service quality [1] Group 1 - The full subsidiary of the company, Shanghai Ruizhi Pharmaceutical Research Group Co., Ltd., has partnered with East China Normal University to develop the new synthesis system [1] - The new system allows for seamless transition from laboratory research to industrial production, indicating a significant advancement in the production process [1] - The implementation of this system is expected to significantly shorten the R&D cycle and improve overall research efficiency [1]

Core Viewpoint - The collaboration between Shanghai Ruizhi Pharmaceutical Research Group and East China Normal University aims to advance drug discovery and delivery systems through the establishment of a cutting-edge technology joint laboratory, focusing on antibody-drug conjugates (ADC) and nucleotide monomer synthesis systems [1] Group 1: Collaboration and Research Focus - The partnership is based on a strategic cooperation framework agreement, emphasizing joint research in drug discovery, biochips, drug delivery systems, and drug conjugates [1] - The newly developed automated, intelligent, and integrated desktop synthesis systems for ADC and nucleotide monomers enable seamless transition from laboratory research to industrial production [1] Group 2: Technological Advancements - The ADC microfluidic manufacturing system integrates ultra-fast laser microfluidic chips with intelligent process control, transitioning antibody drug conjugation from intermittent operations to platform-based manufacturing [1] - The nucleotide monomer microfluidic synthesis system utilizes a catalyst-free and base-free "intelligent microfluidic" approach for the continuous, stable, and green synthesis of phosphoramidite monomers, establishing new standards for the supply of nucleic acid drug materials [1] Group 3: Impact on R&D Efficiency - The implementation of these automated and intelligent synthesis systems is expected to significantly shorten research and development cycles and enhance R&D efficiency, ultimately providing better services to clients [1]

Core Viewpoint - The company has established a cutting-edge technology joint laboratory with East China Normal University to enhance research in drug discovery, biochips, drug delivery systems, and drug conjugates (XDC) [1] Group 1: Collaboration and Research Development - The collaboration is based on a strategic cooperation framework agreement, aiming to advance research in various pharmaceutical fields [1] - The joint efforts have led to the successful development of an automated, intelligent, and integrated desktop synthesis system for antibody-drug conjugates (ADC) and nucleotide monomers [1] Group 2: Technological Advancements - The ADC microfluidic manufacturing system integrates ultra-fast laser microfluidic chips with intelligent process control, transitioning antibody drug conjugation from "batch operation" to "platform-based intelligent manufacturing" [1] - The nucleotide monomer microfluidic synthesis system utilizes a "smart microfluidic" approach without catalysts or alkali participation, enabling continuous, stable, and green synthesis of phosphoramidite monomers [1] Group 3: Impact on R&D Efficiency - The implementation of these automated and intelligent synthesis systems is expected to significantly shorten research and development cycles and enhance R&D efficiency [1] - This advancement will allow the company to provide higher quality services to its clients [1]

基于《战略合作框架协议》的合作背景，公司全资子公司上海睿智医药研究 集团有限公司与华东师大共同组建了前沿技术联合实验室，在药物发现、生物芯 片、药物递送系统、药物偶联物（XDC）等领域开展合作研究。 证券代码：300149 证券简称：睿智医药 公告编号：2025-75 睿智医药科技股份有限公司 关于公司签署战略合作框架协议的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、战略合作概况 睿智医药科技股份有限公司（以下简称"公司"）与华东师范大学（以下简称 "华东师大"）于 2024 年 7 月签署了《战略合作框架协议》。双方本着"资源 共享、优势互补、协同创新、合作共赢"的合作理念，共同致力于建立产学研高 度融合的创新合作体系，致力于新时代药学前沿研究和人才培养，力争打造出医 药创新平台和成果的转化应用和产业化的典范。具体内容详见公司于 2024 年 7 月 8 日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于与华东师范大学签署 <战略合作框架协议>的公告》（公告编号：2024-29）。 二、进展情况 2025 年 11 月 10 ...